Biotech & AI drug discoverySTAT — Biotech

STAT+: Roivant says closely watched immune drug succeeded in new eye disease

Roivant reported positive trials for an immune drug in the eye disease non-infectious uveitis, and the company says the drug could be headed to a new market.

AI summary · generated only from source feed metadata; consult original

Source published2026-10-21T12:05:54+00:00

Published here2026-10-21T12:08:02+00:00

Original source

STAT — Biotech

Media report · consult original reporting

Read the original ↗https://www.statnews.com/2026/10/21/roivant-immune-drug-lisraya-noninfectious-uveitis-trial-results/

Original headline

STAT+: Roivant says closely watched immune drug succeeded in new eye disease

AI bilingual edit · consult original

Headlines are indexed or machine translated, not independent verification of scientific results. Medical news is not clinical advice. Distinguish interstellar concepts from demonstrated space technology using the original source.